{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:27:53Z","timestamp":1793392073632,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["P01 CA66726"],"award-info":[{"award-number":["P01 CA66726"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ymthe.2018.02.015","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T17:45:30Z","timestamp":1519235130000},"page":"1198-1205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion"],"prefix":"10.1016","volume":"26","author":[{"given":"Charu","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura K.","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estuardo","family":"Aguilar-Cordova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea G.","family":"Manzanera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregoria","family":"G\u00f3mez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharyn I.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan W.","family":"Alley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey L.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Bauml","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey J.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Albelda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Sterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2018.02.015_bib1","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1097\/JTO.0b013e3181e95cb8","article-title":"Prognostic factors for survival after surgical palliation of malignant pleural effusion","volume":"5","author":"Pilling","year":"2010","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.ymthe.2018.02.015_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1051-0443(07)61826-0","article-title":"Treatment of malignant pleural effusions with tunneled long-term drainage catheters","volume":"12","author":"Pollak","year":"2001","journal-title":"J.\u00a0Vasc. Interv. Radiol."},{"key":"10.1016\/j.ymthe.2018.02.015_bib3","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/jcb.23126","article-title":"Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development","volume":"112","author":"Aguilar","year":"2011","journal-title":"J.\u00a0Cell. Biochem."},{"key":"10.1016\/j.ymthe.2018.02.015_bib4","doi-asserted-by":"crossref","first-page":"8721","DOI":"10.1016\/S0021-9258(17)34236-9","article-title":"Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine","volume":"253","author":"Fyfe","year":"1978","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2018.02.015_bib5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/hum.1996.7.4-515","article-title":"Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models","volume":"7","author":"Eastham","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.015_bib6","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/(SICI)1097-0215(19991029)83:3<374::AID-IJC13>3.0.CO;2-#","article-title":"Cancer gene therapy with HSV-tk\/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in\u00a0vivo","volume":"83","author":"Kuriyama","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2018.02.015_bib7","first-page":"6228","article-title":"Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component","volume":"54","author":"Vile","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2018.02.015_bib8","first-page":"83","article-title":"Prodrug-activated gene therapy: involvement of an immunological component in the \u201cbystander effect\u201d","volume":"3","author":"Gagandeep","year":"1996","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.015_bib9","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2011.35.5222","article-title":"Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma","volume":"29","author":"Chiocca","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2018.02.015_bib10","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1089\/104303401753204535","article-title":"Prostate-specific antigen response and systemic T\u00a0cell activation after in\u00a0situ gene therapy in prostate cancer patients failing radiotherapy","volume":"12","author":"Miles","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.015_bib11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00262-015-1679-3","article-title":"Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma","volume":"64","author":"Aguilar","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2018.02.015_bib12","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1089\/hum.1996.7.18-2225","article-title":"Safety of intrapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase DNA followed by ganciclovir therapy in nonhuman primates","volume":"7","author":"Kucharczuk","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.015_bib13","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.hoc.2005.09.004","article-title":"Gene therapy for malignant pleural mesothelioma","volume":"19","author":"Sterman","year":"2005","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.ymthe.2018.02.015_bib14","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","article-title":"Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFN\u03b1 combined with chemotherapy","volume":"22","author":"Sterman","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.02.015_bib15","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/ncponc0658","article-title":"Interferon beta adenoviral gene therapy in a patient with ovarian cancer","volume":"3","author":"Sterman","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.ymthe.2018.02.015_bib16","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1164\/rccm.201103-0554CR","article-title":"A trial of intrapleural adenoviral-mediated interferon-\u03b12b gene transfer for malignant pleural mesothelioma","volume":"184","author":"Sterman","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymthe.2018.02.015_bib17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0889-8588(05)70008-3","article-title":"Gene therapy for malignant pleural mesothelioma","volume":"12","author":"Sterman","year":"1998","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.ymthe.2018.02.015_bib18","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","article-title":"A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses","volume":"13","author":"Sterman","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.02.015_bib19","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/mt.2009.309","article-title":"A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions","volume":"18","author":"Sterman","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.02.015_bib20","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1158\/1078-0432.CCR-05-0405","article-title":"Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase\/ganciclovir suicide gene therapy","volume":"11","author":"Sterman","year":"2005","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.ymthe.2018.02.015_bib21","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1089\/hum.1998.9.7-1083","article-title":"Adenovirus-mediated herpes simplex virus thymidine kinase\/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma","volume":"9","author":"Sterman","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.015_bib22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1006\/gyno.2001.6442","article-title":"Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up","volume":"83","author":"Hasenburg","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ymthe.2018.02.015_bib23","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.ijrobp.2003.09.083","article-title":"Phase I-II trial evaluating combined intensity-modulated radiotherapy and in\u00a0situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data","volume":"58","author":"Teh","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ymthe.2018.02.015_bib24","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/neuonc\/now002","article-title":"Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma","volume":"18","author":"Wheeler","year":"2016","journal-title":"Neuro-oncol."},{"key":"10.1016\/j.ymthe.2018.02.015_bib25","first-page":"2055","article-title":"Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in\u00a0vitro drug sensitization system","volume":"54","author":"Smythe","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2018.02.015_bib26","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0022-5223(95)70342-X","article-title":"Differential sensitivity of thoracic malignant tumors to adenovirus-mediated drug sensitization gene therapy","volume":"109","author":"Smythe","year":"1995","journal-title":"J.\u00a0Thorac. Cardiovasc. Surg."},{"issue":"5A","key":"10.1016\/j.ymthe.2018.02.015_bib27","first-page":"3421","article-title":"Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents","volume":"18","author":"Tong","year":"1998","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ymthe.2018.02.015_bib28","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0360-3016(01)01698-4","article-title":"Enhanced therapeutic effect of multiple injections of HSV-TK\u00a0+ GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model","volume":"51","author":"Vlachaki","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ymthe.2018.02.015_bib29","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/mt.2010.159","article-title":"Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms","volume":"18","author":"Fridlender","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.02.015_bib30","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1073\/pnas.91.8.3054","article-title":"Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in\u00a0vivo","volume":"91","author":"Chen","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.02.015_bib31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2018.02.015_bib32","first-page":"7845","article-title":"Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy","volume":"63","author":"DeLong","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2018.02.015_bib33","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2018.02.015_bib34","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1158\/1078-0432.CCR-07-0588","article-title":"Cancer vaccines: moving beyond current paradigms","volume":"13","author":"Schlom","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.02.015_bib35","article-title":"Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients","author":"Lowenstein","year":"2017","journal-title":"Clin. Immunol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618300686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618300686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T17:31:21Z","timestamp":1660498281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001618300686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1525001618300686"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.02.015","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}